La bourse est fermée
  • CAC 40

    5 598,18
    +31,39 (+0,56 %)
     
  • Euro Stoxx 50

    3 527,79
    +16,85 (+0,48 %)
     
  • Dow Jones

    29 910,37
    +37,90 (+0,13 %)
     
  • EUR/USD

    1,1970
    +0,0057 (+0,48 %)
     
  • Gold future

    1 781,90
    -23,60 (-1,31 %)
     
  • BTC-EUR

    14 183,52
    -94,85 (-0,66 %)
     
  • CMC Crypto 200

    333,27
    -4,23 (-1,25 %)
     
  • Pétrole WTI

    45,53
    -0,18 (-0,39 %)
     
  • DAX

    13 335,68
    +49,11 (+0,37 %)
     
  • FTSE 100

    6 367,58
    +4,65 (+0,07 %)
     
  • Nasdaq

    12 205,85
    +111,44 (+0,92 %)
     
  • S&P 500

    3 638,35
    +8,70 (+0,24 %)
     
  • Nikkei 225

    26 644,71
    +107,40 (+0,40 %)
     
  • HANG SENG

    26 894,68
    +75,23 (+0,28 %)
     
  • GBP/USD

    1,3314
    -0,0042 (-0,32 %)
     

Global Genetic Testing Industry

ReportLinker
·24 min de lecture

Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18. 9 Billion as the Burden of Non-Communicable Diseases Grows Bigger. The global market for Genetic Testing is forecast to reach US$18.

New York, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Genetic Testing Industry" - https://www.reportlinker.com/p02284877/?utm_source=GNW
9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the analysis period 2020 through 2027. While deaths due to communicable diseases are expected to decline, mortality rates of non-communicable diseases is forecast to rise significantly. Non-communicable diseases like cardiovascular diseases and cancer represent the leading cause of death, disability and rising healthcare costs worldwide. Predictive genetic testing has the potential to play a key role in fighting this challenge by identifying genetic changes or mutations linked to diseases before onset of symptoms. This helps in effective management of disease progression and mortality by influencing modifiable risk factors and increasing chances of disease prevention. Conventional physician-initiated genetic testing models are intended for individuals with or at the risk of specific medical conditions. Healthcare professionals decide about these tests and order clinical-grade tests from recognized labs. The approach represents the most popular delivery model for genetic testing. The market also encompasses Direct-to-Consumer (DTC) or the consumer-initiated testing model that doesn’t involve a healthcare provider. Hybrid DTC is another model that involves patient-initiated testing along with the participation of medical professional.

Companies offering these tests allow consumers to order tests online while closely working with a genetic counselor or physician network for safeguarding ordering as well as delivery of test results. Another model involves delivery of the elective genetic analysis to people through executive health and wellness clinics. Genetic sequencing relies on three approaches including whole-genome sequencing (WGS), targeted panels and whole-exome sequencing (WES). WGS focuses on reading the complete genome that covers more than 3.3 billion DNA base pairs to understand genome and the role on non-coding regions in influencing disease phenotype and gene expression. However, the method increases turnaround time, is expensive and complicates the data analysis process. In addition, the unavailability of reimbursement has limited the use of WGS for research. On the other hand, approaches to reduce analytical complexity are likely to drive its adoption for clinical use for informed treatment and prognosis. WES sequences the protein-coding exome, and offers a faster and less expensive option and offers deeper sequencing for better accuracy than WGS. The technique holds limited reimbursement for diagnosis of non-specific genetic conditions. WES is a popular approach for complex clinical diagnostics and selection of suitable treatment.

Cancer has emerged as one of the most critical health issues faced by the medical world. As per the National Cancer Institute (NCI), more than 13 million people are diagnosed with cancer each year, with relatively higher incidences noted among men. In the developed as well as the developing countries across the world, cancer is the leading cause of mortality, with the proportion comparatively higher in the developing countries. Major cancers, associated with such chronic infectious conditions as cervix and stomach, have become less common with the economic development of several countries. There is a significant rise in the number of individuals affected by rare cancer conditions such as renal cell carcinoma, GBM, lysosomal storage disorders and acute myeloid leukemia among various other orphan indications of cancer in both developed as well as developing countries. The market for breast cancer gene testing is on the rise, given its preventative aspect against the disease. Each year, in the US, about 250,000 women are newly diagnosed with breast cancer, of which about 10% cases occur due to a hereditary, identifiable gene mutation. Common mutations include those in BRCA½ genes, attributed to 16% of all hereditary breast cancers. Incidence of familial breast cancer is increasing considerably in specific ethnic groups including the Ashkenazi Jews. Predictive gene tests, for instance BRACAnalysis test from Myriad Genetics, identify women at risk. Clinically, the test is suggested for high-risk women with breast cancer in their family circles and women already diagnosed with breast cancer, to determine tumor biology. Apart from the U.S. and Europe, densely populated developing countries such as China harbor the largest potential for breast cancer gene testing market.

Competitors identified in this market include, among others,

  • 23andMe Inc.

  • Abbott Laboratories

  • AutoGenomics Inc.

  • Biocartis NV

  • BioRad Laboratories

  • Cepheid Inc.

  • ELITech Group S.P.A.

  • Illumina Inc.

  • Laboratory Corporation of America Holdings

  • Luminex Corporation

  • Natera Inc.

  • PerkinElmer Inc.

  • QIAGEN N.V.

  • Quest Diagnostics Inc.

  • Roche Diagnostics AG.

  • Roche Molecular Diagnostics Inc.

  • Sequenom Inc.

  • Thermo Fischer Scientific Inc.




Read the full report: https://www.reportlinker.com/p02284877/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
A Prelude to Genetic Testing II-2
Top Ten Genetic Diseases Worldwide II-3
Different Types of Genetic Tests include II-4
Prenatal and New-born Screening II-4
Diagnostic Testing II-4
Predictive & Presymptomatic Testing II-4
Carrier Identification II-4
Pharmacogenomic Testing II-5
List of Genetic Disorders by Event, Genetic Manifestation and
Prevalence II-5
Genetic Testing Delivery Models II-6
Genetic Sequencing Approaches II-6
Genetic Testing Market Witnesses Sluggish Growth during COVID-
19, Set to Regain Momentum Post-COVID 19 II-6
Expanding Applications to Drive Genetic Testing Market II-8
Regional Landscape II-9
Prenatal Testing Market to Rise II-10
Market Outlook II-11

2. FOCUS ON SELECT PLAYERS II-13
Recent Market Activity II-15
World Brands II-17
Innovations II-31

3. MARKET TRENDS & DRIVERS II-32
Studies Indicate Possible Correlation between Genetic
Variations Tied to Immunity and COVID-19 Severity II-32
SEGMENT ANALYSIS II-32
Prenatal Testing - Changing the World of Pregnancy Care II-32
List of Available Prenatal Screening and Diagnostic Tests by
Indication II-33
Players in the Prenatal and New Born Genetic Testing Market II-33
Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky
Affair II-34
Emergence of Non-Invasive Prenatal Diagnosis (NIPD) II-34
Competition Intensifies in the NIPD Market II-35
Select Commercially Available NIPD (Genetic) Tests for
Aneuploidy in the US II-35
Strain on Resources Prevent Wide Adoption of Expanded Carrier
Sequencing II-36
Predictive Diagnostics II-36
Breast Cancer Gene Testing Market to Expand Strongly II-36
Myriad Genetics - A Leader in Breast Cancer Testing II-37
Discovery of Novel Biomarkers Crucial to Predictive Diagnostics II-37
Pharmacogenomics Development Augurs Growth of Genetic Testing
Market II-38
MARKET TRENDS AND GROWTH DRIVERS II-39
Genetic Testing Paves the Way for Personalized Medicine II-39
Exhibit 1: Drug Ineffectiveness for Select Therapeutic
Categories - Necessitating Personalized Medicine II-40
Next-Generation Sequencing (NGS) - A Giant Leap in Genome
Sequencing II-40
Biomarker Discovery Leads to Advanced Genetic Testing II-41
Select List of Available Tumour Markers II-41
Immense Popularity of Ancestry Testing II-44
Increasing Focus on Data Churning II-44
Genetic Testing to Explode into Provider Workflow with
Intriguing Use Cases II-44
Primary Factors Responsible for Waning Interest in Direct-to
Consumer Genetic Testing II-45
Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment II-45
Hybrid Labs to Bridge Gap Between Traditional and DTC Models II-46
Rising Prevalence of Cancer and Chromosomal Disorders Augments
Demand for Cell-Free DNA Testing II-46
Emergence of Rapid DNA Testing II-47
Oncology - A Key Focus Area for Genetic Testing II-47
Exhibit 2: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-48
Ageing Demographics to Drive Demand for Genetic Testing II-48
Exhibit 3: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030 II-49

4. GLOBAL MARKET PERSPECTIVE II-50
Table 1: World Current & Future Analysis for Genetic Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-50

Table 2: World Historic Review for Genetic Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-51

Table 3: World 15-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027 II-52

Table 4: World Current & Future Analysis for Prenatal & Newborn
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-53

Table 5: World Historic Review for Prenatal & Newborn by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-54

Table 6: World 15-Year Perspective for Prenatal & Newborn by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-55

Table 7: World Current & Future Analysis for Diagnostic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-56

Table 8: World Historic Review for Diagnostic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-57

Table 9: World 15-Year Perspective for Diagnostic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027 II-58

Table 10: World Current & Future Analysis for Predictive &
Presymptomatic by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 II-59

Table 11: World Historic Review for Predictive & Presymptomatic
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-60

Table 12: World 15-Year Perspective for Predictive &
Presymptomatic by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027 II-61

Table 13: World Current & Future Analysis for Carrier by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-62

Table 14: World Historic Review for Carrier by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-63

Table 15: World 15-Year Perspective for Carrier by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027 II-64

Table 16: World Current & Future Analysis for Pharmacogenomic
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-65

Table 17: World Historic Review for Pharmacogenomic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-66

Table 18: World 15-Year Perspective for Pharmacogenomic by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-67

Table 19: World Current & Future Analysis for Other Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-68

Table 20: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 II-69

Table 21: World 15-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-70

Table 22: World Current & Future Analysis for Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-71

Table 23: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 II-72

Table 24: World 15-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027 II-73

Table 25: World Current & Future Analysis for Genetic Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 II-74

Table 26: World Historic Review for Genetic Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-75

Table 27: World 15-Year Perspective for Genetic Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-76

Table 28: World Current & Future Analysis for Cardiovascular
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 II-77

Table 29: World Historic Review for Cardiovascular Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-78

Table 30: World 15-Year Perspective for Cardiovascular Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-79

Table 31: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 II-80

Table 32: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 II-81

Table 33: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027 II-82

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
Use of Genomic Data in Clinical Settings to Gather Pace III-1
The United States: Leading Market for Genetic Testing Globally III-1
Predictive Screening: Another Growth Area III-2
Growing Relevance of Personalized Medicine Augurs Well III-2
Rising Incidence of Cancer in the US: Driver for Cancer Genetic
Testing III-3
Exhibit 4: Estimated Number of New Cancer Cases and Deaths in
the US (2019) III-4
Newborn Testing Gains Ground III-4
Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal
Testing III-6
Coverage of NIPT in Average Risk Pregnancies Expands Target Market III-6
Direct-to-Consumer Testing III-6
Favourable Reimbursement Policies III-7
Favourable Insurance Coverage for Cystic Fibrosis Genetic Testing III-7
Demographic Changes Offer Growth Opportunities III-8
Exhibit 5: North American Aging Population by Age Group: 1975-2050 III-8
Skepticism Limits Widespread Adoption of Genetic Testing III-8
Competitive Overview III-9
Myriad Eyes Diversification and Expansion for Growth III-9
Natera Holds Forte in the NIPT Market III-9
Invitae Banks on Low Cost Solutions for Expanding Revenues III-10
Regulatory Environment III-10
Genetic Information Nondiscrimination Act Boosts Genetic Testing III-11
Stricter Regulations for DTC Genetic Testing III-11
FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests III-12
Select Genetic Test Reimbursement Codes III-13
Market Analytics III-19
Table 34: USA Current & Future Analysis for Genetic Testing by
Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-19

Table 35: USA Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-20

Table 36: USA 15-Year Perspective for Genetic Testing by Type -
Percentage Breakdown of Value Sales for Prenatal & Newborn,
Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-21

Table 37: USA Current & Future Analysis for Genetic Testing by
Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-22

Table 38: USA Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-23

Table 39: USA 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-24

CANADA III-25
Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand III-25
Exhibit 6: Number of New Cancer Cases in Canada: 2019 III-25
Regulatory Scenario III-26
Market Analytics III-26
Table 40: Canada Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-26

Table 41: Canada Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-27

Table 42: Canada 15-Year Perspective for Genetic Testing by
Type - Percentage Breakdown of Value Sales for Prenatal &
Newborn, Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-28

Table 43: Canada Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-29

Table 44: Canada Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-30

Table 45: Canada 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-31

JAPAN III-32
Demographics Drive Market Growth III-32
DTC Genetic Testing Regulatory Scenario III-32
Market Analytics III-33
Table 46: Japan Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-33

Table 47: Japan Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-34

Table 48: Japan 15-Year Perspective for Genetic Testing by Type -
Percentage Breakdown of Value Sales for Prenatal & Newborn,
Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-35

Table 49: Japan Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-36

Table 50: Japan Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-37

Table 51: Japan 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-38

CHINA III-39
Market Overview III-39
China Attracts Domestic and Foreign Players III-39
Strong Focus on Genomics III-40
Genetic Testing to Reveal Real Talent in Children - A New
Popular Application III-40
China to Take Lead in Rapidly Growing Asian Genomics Market III-41
Market Analytics III-42
Table 52: China Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-42

Table 53: China Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-43

Table 54: China 15-Year Perspective for Genetic Testing by Type -
Percentage Breakdown of Value Sales for Prenatal & Newborn,
Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-44

Table 55: China Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-45

Table 56: China Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-46

Table 57: China 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-47

EUROPE III-48
European Personalized Medicine Market to Exhibit Robust Growth III-48
Aging Population to Drive Demand for Genetic Testing III-48
Exhibit 7: European Population by Age Group (2016, 2030 & 2050):
Percentage Share Breakdown by Age Group for 0-14, 15-64,
and 65 & Above III-48
Legislations/Regulatory Policies in Select European Countries III-49
Legislations Governing Genetic Testing in Select European
Countries III-50
Rising Cancer Incidence Augurs Well for European Genetic
Testing Market III-50
Exhibit 8: Cancer Incidence in Europe: Number of New Cancer
Cases (in Thousands) by Site for 2018 III-51
Market Analytics III-52
Table 58: Europe Current & Future Analysis for Genetic Testing
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 III-52

Table 59: Europe Historic Review for Genetic Testing by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 III-53

Table 60: Europe 15-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027 III-54

Table 61: Europe Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-55

Table 62: Europe Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-56

Table 63: Europe 15-Year Perspective for Genetic Testing by
Type - Percentage Breakdown of Value Sales for Prenatal &
Newborn, Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-57

Table 64: Europe Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-58

Table 65: Europe Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-59

Table 66: Europe 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-60

FRANCE III-61
Table 67: France Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-61

Table 68: France Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-62

Table 69: France 15-Year Perspective for Genetic Testing by
Type - Percentage Breakdown of Value Sales for Prenatal &
Newborn, Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-63

Table 70: France Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-64

Table 71: France Historic Review for Genetic Testing by Genetic
Testing - Cancer, Genetic Disease, Cardiovascular Disease and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 III-65

Table 72: France 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-66

GERMANY III-67
Parliamentary Regulations III-67
Market Analytics III-68
Table 73: Germany Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-68

Table 74: Germany Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 III-69

Table 75: Germany 15-Year Perspective for Genetic Testing by
Type - Percentage Breakdown of Value Sales for Prenatal &
Newborn, Diagnostic, Predictive & Presymptomatic, Carrier,
Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027 III-70

Table 76: Germany Current & Future Analysis for Genetic Testing
by Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 III-71

Table 77: Germany Historic Review for Genetic Testing by
Genetic Testing - Cancer, Genetic Disease, Cardiovascular
Disease and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 III-72

Table 78: Germany 15-Year Perspective for Genetic Testing by
Genetic Testing - Percentage Breakdown of Value Sales for
Cancer, Genetic Disease, Cardiovascular Disease and Other
Applications for the Years 2012, 2020 & 2027 III-73

ITALY III-74
Table 79: Italy Current & Future Analysis for Genetic Testing
by Type - Prenatal & Newborn, Diagnostic, Predictive &
Presymptomatic, Carrier, Pharmacogenomic and Other Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 III-74

Table 80: Italy Historic Review for Genetic Testing by Type -
Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic,
Carrier, Pharmacogenomic and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p02284877/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001